Top

Published in:

01-06-2020 | Breast Cancer | Preclinical study

PD-L1 diagnostics in the neoadjuvant setting: implications of intratumoral heterogeneity of PD-L1 expression in triple negative breast cancer for assessment in small biopsies

Published in: Breast Cancer Research and Treatment | Issue 3/2020

Abstract

Purpose

PD-L1 expression is a predictive biomarker for anti-PD-L1 immunotherapy in triple negative breast cancer (TNBC). In the neoadjuvant setting, immunohistochemical (IHC) evaluation of PD-L1 expression can only be performed on small tissue biopsies. In our study we investigated heterogeneity of PD-L1 expression in TNBC, and how reliably PD-L1 expression in small tissue samples reflects PD-L1 expression in larger tumor sections in TNBC.

Methods

Tissue microarrays (TMAs) were constructed from surgical specimens of 110 patients with TNBC. TMAs contained 4 cores (1 mm in diameter) per patient. To evaluate PD-L1 expression, TMAs were stained with PD-L1 IHC 22C3 PharmDx. Single-core PD-L1 expression was compared to overall PD-L1 expression of each patient’s tumor, to ascertain how often small samples of tumor tissue show the same PD-L1 expression as larger tumor samples.

Results

Our study found substantial heterogeneity of PD-L1 expression between different TMA cores from the same patient. Heterogeneity was greater in immune cells (ICs) than in tumor cells, in large part due to the uneven distribution of ICs in the tumor. For IC PD-L1 expression, we found that sensitivity can be as low as 0.81 for detecting PD-L1 expression at the 1% threshold most commonly used in breast cancer. Negative predictive value for ICs was 0.7.

Conclusions

There is substantial heterogeneity of PD-L1 expression between small tissue samples from the same TNBC tumor, especially for IC expression. This poses challenges for evaluation of PD-L1 expression in the neoadjuvant setting. Negative biopsies should prompt further investigation, and multiple biopsies might be necessary.

Reis-Filho JS, Tutt ANJ (2007) Triple negative tumours: a critical review. Histopathology 52:108–118. https://doi.org/10.1200/JCO.2007.13.1748 CrossRef

Bianchini G, Balko JM, Mayer IA et al (2016) Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 13:674–690. https://doi.org/10.1038/nrclinonc.2016.66 CrossRefPubMedPubMedCentral

Schmid P, Adams S, Rugo HS et al (2018) Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 379:2108–2121. https://doi.org/10.1056/NEJMoa1809615 CrossRefPubMed

Dill EA, Gru AA, Atkins KA et al (2017) PD-L1 expression and intratumoral heterogeneity across breast cancer subtypes and stages: an assessment of 245 primary and 40 metastatic tumors. Am J Surg Pathol 41:334–342. https://doi.org/10.1097/PAS.0000000000000780 CrossRefPubMed

Yuan C, Liu Z, Yu Q et al (2019) Expression of PD-1/PD-L1 in primary breast tumours and metastatic axillary lymph nodes and its correlation with clinicopathological parameters. Sci Rep 9(1):14356. https://doi.org/10.1038/s41598-019-50898-3 CrossRefPubMedPubMedCentral

Manson QF, Schrijver WAME, ter Hoeve ND et al (2019) Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases. Clin Exp Metastasis 36:29–37. https://doi.org/10.1007/s10585-018-9950-6 CrossRefPubMed

Ogiya R, Niikura N, Kumaki N et al (2016) Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients. Cancer Sci 107:1730–1735. https://doi.org/10.1111/cas.13101 CrossRefPubMedPubMedCentral

Cimino-Mathews A, Thompson E, Taube JM et al (2016) PD-L1 (B7–H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Hum Pathol 47:52–63. https://doi.org/10.1016/j.humpath.2015.09.003 CrossRefPubMed

Munari E, Zamboni G, Lunardi G et al (2018) PD-L1 expression heterogeneity in non-small cell lung cancer: defining criteria for harmonization between biopsy specimens and whole sections. J Thorac Oncol 13:1113–1120. https://doi.org/10.1016/j.jtho.2018.04.017 CrossRefPubMed

10.

Camp RL, Charette LA, Rimm DL (2000) Validation of tissue microarray technology in breast carcinoma. Lab Investig 80:1943–1949. https://doi.org/10.1038/labinvest.3780204 CrossRefPubMed

11.

Narayan P, Wahby S, Gao JJ et al (2020) FDA approval summary: atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic TNBC whose tumors express PD-L1. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-19-3545 CrossRefPubMed

12.

Abstract (2019) Abstracts: 31st European Congress of Pathology (2019). Virchows Arch 475:1–436. https://doi.org/10.1007/s00428-019-02631-8 CrossRef

13.

Chen DS, Mellman I (2017) Elements of cancer immunity and the cancer-immune set point. Nature 541(7637):321–330. https://doi.org/10.1038/nature21349 CrossRefPubMed

14.

Rimm DL, Han G, Taube JM et al (2017) A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non–small cell lung cancer. JAMA Oncol 3:1051–1058. https://doi.org/10.1001/jamaoncol.2017.0013 CrossRefPubMedPubMedCentral

15.

Gniadek TJ, Li QK, Tully E et al (2017) Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy. Mod Pathol 30:530–538. https://doi.org/10.1038/modpathol.2016.213 CrossRefPubMed

16.

Gagné A, Enlow W, Pigeon M-A et al (2018) Comprehensive assessment of PD-L1 staining heterogeneity in pulmonary adenocarcinomas using tissue microarrays: impact of the architecture pattern and the number of cores. Am J Surg Pathol 42:687–694. https://doi.org/10.1097/PAS.0000000000001013 CrossRefPubMed

17.

Kitazono S, Fujiwara Y, Tsuta K et al (2015) Reliability of small biopsy samples compared with resected specimens for the determination of programmed death-ligand 1 expression in non-small-cell lung cancer. Clin Lung Cancer 16:385–390. https://doi.org/10.1016/j.cllc.2015.03.008 CrossRefPubMed

18.

Haragan A, Field JK, Davies MPA et al (2019) Heterogeneity of PD-L1 expression in non-small cell lung cancer: implications for specimen sampling in predicting treatment response. Lung Cancer 134:79–84. https://doi.org/10.1016/j.lungcan.2019.06.005 CrossRefPubMedPubMedCentral

19.

Gradecki SE, Grange JS, Stelow EB (2018) Concordance of PD-L1 expression between core biopsy and resection specimens of non-small cell lung cancer. Am J Surg Pathol 42:1090–1094. https://doi.org/10.1097/PAS.0000000000001085 CrossRefPubMed

20.

Munari E, Zamboni G, Marconi M et al (2017) PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability. Oncotarget 8:90123–90131CrossRef

21.

Li C, Huang C, Mok TS et al (2017) Comparison of 22C3 PD-L1 expression between surgically resected specimens and paired tissue microarrays in non-small cell lung cancer. J Thorac Oncol 12:1536–1543. https://doi.org/10.1016/j.jtho.2017.07.015 CrossRefPubMed

Title: PD-L1 diagnostics in the neoadjuvant setting: implications of intratumoral heterogeneity of PD-L1 expression in triple negative breast cancer for assessment in small biopsies
Publication date: 01-06-2020
Keywords: Breast Cancer
Breast Cancer
Biomarkers
Published in: Breast Cancer Research and Treatment / Issue 3/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-020-05655-w

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2020

HER2 intratumoral heterogeneity is independently associated with distal metastasis and overall survival in HER2-positive breast carcinomas

Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium

Is there any association between absolute lymphocyte count and increased tumor-infiltrating lymphocytes in metastatic sites in advanced breast cancer patients who get benefit from eribulin treatment?

Tumour characteristics and survivorship in a cohort of breast cancer: the MCC-Spain study

Circulating tumour cell enumeration does not correlate with Miller–Payne grade in a cohort of breast cancer patients undergoing neoadjuvant chemotherapy

The supplemental value of mammographic screening over breast MRI alone in BRCA2 mutation carriers

Keynote webinar | Spotlight on antibody–drug conjugates in cancer